Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × cetrorelix × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1

Interventions

Carboplatin 265 Paclitaxel 260 Cisplatin 212 Docetaxel 205 pembrolizumab 190 Gemcitabine 181 Pemetrexed 134 Rituximab 126 Capecitabine 124 Bevacizumab 117 Dexamethasone 103 Fluorouracil 98 Cyclophosphamide 91 Doxorubicin 90 Prednisone 85 Trastuzumab 83 Nivolumab 77 Oxaliplatin 75 atezolizumab 64 durvalumab 62 Leucovorin 59 Injections 59 Lenalidomide 56 130-nm albumin-bound paclitaxel 56 Irinotecan 49 Drug Therapy 48 Fulvestrant 46 Bortezomib 46 Letrozole 43 Bendamustine Hydrochloride 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01185704 2014-02-13

ATTAC-PCO

Merck KGaA, Darmstadt, Germany

Phase 3 Completed

136 enrolled 21 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡